2 active not recruiting, 1 completed, 1 recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Unresectable Bladder Urothelial Carcinoma: new trials by email Literature Review of Unresectable Bladder Urothelial Carcinoma trials Research Report on Unresectable Bladder Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
Ureteral Neoplasms (4) · Urinary Bladder Neoplasms (4) · Urethral Neoplasms (3) · Carcinoma, Transitional Cell (2)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Ureteral Diseases (4) · Urinary Bladder Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Urologic Diseases (4) · Urologic Neoplasms (4) · Urethral Diseases (3) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2)
Biopsy (3) · Specimen Handling (3) · Magnetic Resonance Spectroscopy (2) · atezolizumab (2) · Contrast Media (1) · Interleukin-7 (1) · Nivolumab (1) · enfortumab vedotin (1) · eribulin (1) · pembrolizumab (1) · quemliclustat (1) · relatlimab (1)
National Cancer Institute (NCI) (2) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1)
United States (4)
Anishka A D'Souza (1) · Evan Y Yu (1) · Rosa Nadal Rios, MD, PhD (1) · Sangeeta Goswami (1)
P30CA015704 (1), U01CA154967 (1), UM1CA186717 (1)